Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Mesenchymal Stem Cells

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Multiple sclerosis and related disorders·2026

Same author

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026

Same author

Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the harmonized CSF analysis for MS investigation (hCAMI) subcommittee of the Canadian society of clinical chemists (CSCC).

Clinical biochemistry·2026

Same author

Demographic and Clinical Characteristics of Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder in Canadian Adults.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026

Same author

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Neurology·2025

Search research articles

Related Experiment Video

Updated: May 16, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned.

Harold L Atkins¹, Mark S Freedman

¹Ottawa Hospital Research Institute, Ottawa, Canada. hatkins@ohri.ca

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics

|November 30, 2012

Summary

Hematopoietic stem cell transplants (HSCT) offer a promising treatment for aggressive multiple sclerosis. This approach can halt disease progression and reduce disability by regenerating the immune system without long-term medication.

More Related Videos

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

Related Experiment Videos

Last Updated: May 16, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

Area of Science:

Immunology
Neurology
Transplantation Medicine

Background:

Over 600 hematopoietic stem cell transplants (HSCT) for multiple sclerosis have been reported in the last 15 years.
HSCT involves harvesting and storing a patient's own stem cells, followed by high-dose chemotherapy to eliminate the immune system, and then reinfusion to regenerate it.

Purpose of the Study:

To discuss the top 10 lessons learned from extensive clinical experience with HSCT for multiple sclerosis treatment.
To highlight the potential of HSCT in managing aggressive forms of multiple sclerosis.

Main Methods:

Review of clinical literature reporting on over 600 HSCT procedures for multiple sclerosis.
Analysis of patient selection criteria and peri-transplant management strategies.
Evaluation of treatment outcomes, including relapse rates, disease progression, and disability.

Main Results:

Increasing clinical experience has led to refined patient selection and peri-transplant management, reducing treatment-related complications.
HSCT can significantly reduce or eliminate relapses in patients with aggressive multiple sclerosis.
This treatment can halt disease progression and decrease disability burden in some patients, obviating the need for chronic disease-modifying agents.

Conclusions:

Hematopoietic stem cell transplantation is a viable and effective treatment for aggressive multiple sclerosis.
Continued refinement of HSCT protocols is improving patient outcomes and reducing complications.
HSCT offers a potentially curative approach for select multiple sclerosis patients, improving long-term quality of life.